Expression of peritumoral SPARC during distal cholangiocarcinoma progression and correlation with outcome

References

• Kirstein MM, Vogel A. Epidemiology and risk factors of cholangiocarcinoma. Visc Med. 2016;32(6):395–400.
   PubMed Web of Science ®Google Scholar
• Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):221–232.
   PubMed Web of Science ®Google Scholar
• Mosconi S, Beretta GD, Labianca R, et al. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2009;69(3):259–270.
   PubMed Web of Science ®Google Scholar
• Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–1669.
   PubMed Web of Science ®Google Scholar
• Khan AS, Dageforde LA. Cholangiocarcinoma. Surg Clin North Am. 2019;99(2):315–335.
   PubMed Web of Science ®Google Scholar
• Kendall T, Verheij J, Gaudio E, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):7–18.
   PubMed Web of Science ®Google Scholar
• Bragazzi MC, Ridola L, Safarikia S, et al. New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin. Ann Gastroenterol. 2018;31(1):42–55.
   PubMed Web of Science ®Google Scholar
• Byrling J, Andersson B, Marko-Varga G, et al. Cholangiocarcinoma-current classification and challenges towards personalised medicine. Scand J Gastroenterol. 2016;51(6):641–643.
   PubMed Web of Science ®Google Scholar
• Sirica AE, Gores GJ. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology. 2014;59(6):2397–2402.
   PubMed Web of Science ®Google Scholar
• Brivio S, Cadamuro M, Strazzabosco M, et al. Tumor reactive stroma in cholangiocarcinoma: the fuel behind cancer aggressiveness. World J Hepatol. 2017;9(9):455–468.
   PubMed Web of Science ®Google Scholar
• Cadamuro M, Stecca T, Brivio S, et al. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochim Biophys Acta. 2018;1864(4 Pt B):1435–1443.
   Web of Science ®Google Scholar
• Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest. 2001;107(9):1049–1054.
   PubMed Web of Science ®Google Scholar
• Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 2001;19(8):815–827.
   Google Scholar
• Rivera LB, Bradshaw AD, Brekken RA. The regulatory function of SPARC in vascular biology. Cell Mol Life Sci. 2011;68(19):3165–3173.
   PubMed Web of Science ®Google Scholar
• Delany AM, Hankenson KD. Thrombospondin-2 and SPARC/osteonectin are critical regulators of bone remodeling. J Cell Commun Signal. 2009;3(3-4):227–238.
   PubMed Web of Science ®Google Scholar
• Bradshaw AD. The role of SPARC in extracellular matrix assembly. J Cell Commun Signal. 2009;3(3–4):239–246.
   PubMed Web of Science ®Google Scholar
• Bradshaw AD. Diverse biological functions of the SPARC family of proteins. Int J Biochem Cell Biol. 2012;44(3):480–488.
   PubMed Web of Science ®Google Scholar
• Nagaraju GP, Dontula R, El-Rayes BF, et al. Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis. Carcinogenesis. 2014;35(5):967–973.
   PubMed Web of Science ®Google Scholar
• Arnold SA, Brekken RA. SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal. 2009;3(3–4):255–273.
   PubMed Web of Science ®Google Scholar
• Ma Y, Chen H, Ma H, et al. Prognostic role of secreted protein acidic and rich in cysteine in patients with solid tumors. Saudi Med J. 2019;40(8):755–765.
   PubMed Web of Science ®Google Scholar
• Cheng CT, Chu YY, Yeh CN, Huang SC, et al. Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma. Onco Targets Ther. 2015;8:1899–1907.
   PubMed Web of Science ®Google Scholar
• Toyota K, Murakami Y, Kondo N, et al. Impact of secreted protein acidic and rich in cysteine (SPARC) expression on prognosis after surgical resection for biliary carcinoma. J Gastrointest Surg. 2017;21(6):990–999.
   PubMed Web of Science ®Google Scholar
• Nakashima S, Kobayashi S, Sakai D, et al. Prognostic impact of tumoral and/or peri-tumoral stromal SPARC expressions after surgery in patients with biliary tract cancer. J Surg Oncol. 2014;110(8):1016–1022.
   PubMed Web of Science ®Google Scholar
• Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system. 4th ed. Lyon: World Health Organization; International Agency for Research on Cancer; 2019.
   Google Scholar
• Edge S, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York (NY): Springer Verlag; 2010.
   Google Scholar
• Markov P, Satoi S, Kon M. Redefining the R1 resection in patients with pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2016;23(9):523–532.
   PubMed Web of Science ®Google Scholar
• McCart Reed AE, Kutasovic JR, Vargas AC, et al. An epithelial to mesenchymal transition programme does not usually drive the phenotype of invasive lobular carcinomas. J Pathol. 2016;238(4):489–494.
   PubMed Web of Science ®Google Scholar
• Lindner JL, Loibl S, Denkert C, et al. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol. 2015;26(1):95–100.
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Seitz J, Smetanay K, et al. Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer. Anticancer Res. 2014;34(11):6609–6615.
   PubMed Web of Science ®Google Scholar
• Sinn M, Sinn BV, Striefler JK, et al. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol. 2014;25(5):1025–1032.
   PubMed Web of Science ®Google Scholar
• Gundewar C, Sasor A, Hilmersson KS, et al. The role of SPARC expression in pancreatic cancer progression and patient survival. Scand J Gastroenterol. 2015;50(9):1170–1174.
   PubMed Web of Science ®Google Scholar
• Sung S-Y, Chang J-L, Chen K-C, et al. Co-targeting prostate cancer epithelium and bone stroma by human osteonectin-promoter-mediated suicide gene therapy effectively inhibits androgen-independent prostate cancer growth. PLOS One. 2016;11(4):e0153350–e.
   PubMed Web of Science ®Google Scholar
• Thomas S, Waterman P, Chen S, et al. Development of secreted protein and acidic and rich in cysteine (SPARC) targeted nanoparticles for the prognostic molecular imaging of metastatic prostate cancer. J Nanomed Nanotechnol. 2011;2(112):2157–7439.
   PubMedGoogle Scholar
• Wang L, Yang M, Shan L, et al. The role of SPARC protein expression in the progress of gastric cancer. Pathol Oncol Res. 2012;18(3):697–702.
   PubMed Web of Science ®Google Scholar
• Ormanns S, Haas M, Baechmann S, et al. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials. Br J Cancer. 2016;115(12):1520–1529.
   PubMed Web of Science ®Google Scholar
• Altman DG, McShane LM, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLOS Med. 2012;9(5):e1001216.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387–391.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yoshino S, Kanekiyo S, et al. High secreted protein acidic and rich in cysteine expression in peritumoral fibroblasts predicts better prognosis in patients with resectable gastric cancer. Oncol Lett. 2018;15(1):803–812.
   PubMed Web of Science ®Google Scholar
• Bloomston M, Ellison EC, Muscarella P, et al. Stromal osteonectin overexpression is associated with poor outcome in patients with ampullary cancer. Ann Surg Oncol. 2006;14(1):211–217.
   PubMed Web of Science ®Google Scholar
• Liang C, Shi S, Meng Q, et al. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer? Cell Mol Life Sci. 2018;75(6):1001–1012.
   PubMed Web of Science ®Google Scholar
• Giordano G, Pancione M, Olivieri N, et al. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol. 2017;23(32):5875–5886.
   PubMed Web of Science ®Google Scholar